Fig. 6: Changes in fever symptom, lymphocyte counts, and inflammation markers of individual patients.
From: Efficacy and tolerability of bevacizumab in patients with severe Covid-19
Dynamic changes in fever status of 14 BEVA (bevacizumab)-treated patients who had a fever at enrollment (a). Day 0 marks the time point for initiating bevacizumab treatment; red, orange, and blue columns indicate the duration of fever or normal body temperature status before and after BEVA treatment; and diamonds represent discharge. Numbers along the vertical axis represent the patient numbers that match Fig. 2. Changes of lymphocyte counts (n = 14) (b) and C-reactive protein (CRP) levels (n = 9) (c) before and after BEVA treatment were analyzed by the Wilcoxon signed-rank test. The center lines of boxes represent median values; the lower and upper hinges represent the 25th and 75th percentiles (Q1 and Q3), the range between which represents the interquartile range (IQR); whiskers correspond to the highest or lowest values of non-outlier data (within 1.5 × IQR from the lower or upper hinges); numbers on the horizontal lines represent p-values. The red dots represent the data of individual treated patients. p < 0.05 for two-tailed hypothesis tests was considered statistically significant. Source data are provided as a Source Data file.
